摘要
Neoadjuvant chemotherapy with folinic acid,5-fluorouracil,irinotecan and oxaliplatin(FOLFIRINOX)or gemcitabine plus nab-paclitaxel(Gem-nabP)for 4 to 6 months,potentially followed by chemoradiotherapy and an attempt for surgical resection for select patients,represents the multidisciplinary care standard for borderline resectable(BRPC)and locally advanced pancreatic ductal adenocarcinoma(LAPC)patients with good performance status(1,2).With neoadjuvant therapy,resection rates average 65%and survival ranges from 22-29 months for BRPC,whereas LAPC patients have resection rates of 15-20%and survival of 16-24 months,respectively(3-5).
